Butaclamol hydrochloride in newly admitted schizophrenics

L. E. Hollister, K. L. Davis, P. A. Berger

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Butaclamol hydrochloride, a new type of antipsychotic drug, was evaluated by an uncontrolled study of 13 newly admitted schizophrenic patients. The drug had antipsychotic effects as well as a strong propensity for evoking extrapyramidal side effects. With the maximal daily doses of 30 mg used in this study, therapeutic results obtained were probably somewhat less than optimal.

Original languageEnglish
Pages (from-to)493-500
Number of pages8
JournalPsychopharmacology Communications
Issue number5
StatePublished - 1975
Externally publishedYes


Dive into the research topics of 'Butaclamol hydrochloride in newly admitted schizophrenics'. Together they form a unique fingerprint.

Cite this